arrow
E

Eleanor Walsh

University of Bristol
H指数:23
被引数:6,649

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality

前列腺特异性抗原筛查与15年前列腺癌死亡率

2024-05-0718
PRE
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

前列腺癌监测、手术或放疗后的15年预后

2023-04-27295
OA
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)

局限性前列腺癌治疗的功能和生活质量结果 (前列腺癌检测和治疗 [ProtecT] 研究)

2022-05-0347
OA
A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data

个性化前列腺癌筛查的遗传风险评分,应用于人口数据

2020-09-0128
OAAI
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received (vol 77, pg 320, 2020)
2020-09-011
OAAI
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT
2020-08-0133
OA
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer
2020-07-1613
OAAI
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received
2020-03-01116
OAAI
The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression
2020-02-1240
OAAI
Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality The CAP Randomized Clinical Trial

基于低强度PSA的筛查干预对前列腺癌死亡率的影响CAP随机临床试验

2018-03-06322
OAAI
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

局限性前列腺癌监测、手术或放疗后的10年预后

2016-10-132.1K
OAAI
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

前列腺癌监测、手术或放疗后患者报告的结果

2016-10-13971
OAAI
Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee
2016-06-0241
OAAI